Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + docetaxel + cisplatin
- Development stage
- Phase 3
- Lead developer
- Shanghai Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of the PD-1 inhibitor toripalimab and the chemotherapy agents docetaxel and cisplatin. It is being investigated as induction chemotherapy for patients with localized or locally advanced hypopharyngeal squamous cell carcinoma (HPSCC). Toripalimab is a monoclonal antibody that blocks the interaction between the PD-1 receptor and its ligands (PD-L1 and PD-L2), thereby enhancing the immune system's ability to recognize and attack tumor cells. Docetaxel is a taxane that stabilizes microtubules, preventing their depolymerization and leading to cell cycle arrest. Cisplatin is a platinum-based alkylating agent that forms DNA cross-links, interfering with DNA repair and synthesis. The regimen is being evaluated by the Peking Union Medical College Hospital to improve laryngeal preservation rates and reduce tumor burden prior to surgery or radical chemoradiotherapy.
- Brand names
- Tuoyi
- Other names
- TP + PD-1 regimenToripalimab/Docetaxel/Cisplatin
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on toripalimab + docetaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + docetaxel + cisplatin.